What is it about?
There are diseases whose diagnosis is not always easy. In doubtful cases, it is sometimes difficult to exclude or confirm the condition. Ophthalmologists and Neurologists know about glaucoma and Alzheimer's disease, respectively. Today we are proud to say that we are winning our challenge. We developed a new electrophysiological test that we call RE-PERG, a variation of steady-state erg pattern. In previously published works, we showed that our analysis can discriminate between early glaucoma patients and healthy, and, subsequently, that it is not influenced by cataract and myopia in this work. Briefly, we found a fast and straightforward protocol for identification of retinal ganglion cell dysfunction and we discovered that our test can detect inner retinal impairment in glaucoma.
Featured Image
Why is it important?
Having a reliable biological marker means having the opportunity to test the effects of treatment, especially when the procedure is as sensitive to change as our RE-PERG.
Perspectives
We are working for another indication of the RE-PERG, and it will be our next work.
Alberto Mavilio
Azienda Sanitaria Locale Brindisi
Read the Original
This page is a summary of: RE-PERG, a new paradigm for glaucoma diagnosis, in myopic eyes, Clinical Ophthalmology, July 2019, Dove Medical Press,
DOI: 10.2147/opth.s211337.
You can read the full text:
Contributors
The following have contributed to this page







